Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Travoprost - Glaukos

Next Previous
Drug Profile

Travoprost - Glaukos

Alternative Names: iDose TR; iDose TR - Glaukos; iDose Travoprost; Travoprost implant - Glaukos; Travoprost intracameral implant – Glaukos; Travoprost intraocular implant – Glaukos

Latest Information Update: 03 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dose medical corporation
  • Developer Glaukos Corporation
  • Class Antiglaucomas; Eye disorder therapies; Prostaglandins; Small molecules
  • Mechanism of Action Prostaglandin F2 alpha agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ocular hypertension; Open-angle glaucoma
  • Phase III Glaucoma

Most Recent Events

  • 17 Feb 2026 Phase-III clinical trials in Glaucoma (Diagnosis) in USA (Intraocular) (NCT07495852)
  • 28 Jan 2026 US FDA approves NDA labeling supplement application of iDose® TR using a repeat treatment protocol
  • 19 Jun 2024 Glaukos completes a phase III trial for Open-angle glaucoma and Ocular hypertension in USA (NCT03868124)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top